Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing...
.png)
Market Touch Signal · Finland · international digital desk
+358 400 512311
info@market-touch.org
